Asif Ali Sells 1,234 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGXGet Free Report) CFO Asif Ali sold 1,234 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the sale, the chief financial officer now owns 37,163 shares of the company’s stock, valued at $933,162.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Asif Ali also recently made the following trade(s):

  • On Friday, March 1st, Asif Ali sold 14,248 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $32.24, for a total transaction of $459,355.52.

Protagonist Therapeutics Price Performance

PTGX opened at $25.61 on Monday. The company’s 50-day moving average is $28.52 and its 200 day moving average is $23.01. Protagonist Therapeutics, Inc. has a fifty-two week low of $13.72 and a fifty-two week high of $33.34. The firm has a market capitalization of $1.49 billion, a P/E ratio of -17.19 and a beta of 2.01.

Protagonist Therapeutics (NASDAQ:PTGXGet Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.39. The firm had revenue of $60.00 million for the quarter, compared to the consensus estimate of $60.00 million. On average, equities research analysts expect that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of research reports. StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Protagonist Therapeutics in a research note on Wednesday, February 28th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Get Our Latest Analysis on PTGX

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PTGX. State Street Corp lifted its position in shares of Protagonist Therapeutics by 108.1% during the second quarter. State Street Corp now owns 6,776,269 shares of the company’s stock valued at $53,600,000 after purchasing an additional 3,519,461 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Protagonist Therapeutics by 135.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,613,453 shares of the company’s stock valued at $59,926,000 after purchasing an additional 1,505,313 shares in the last quarter. Braidwell LP bought a new stake in Protagonist Therapeutics in the third quarter worth about $18,501,000. Perceptive Advisors LLC bought a new stake in Protagonist Therapeutics in the first quarter worth about $22,198,000. Finally, Kynam Capital Management LP raised its position in Protagonist Therapeutics by 86.5% in the third quarter. Kynam Capital Management LP now owns 1,818,657 shares of the company’s stock worth $30,335,000 after acquiring an additional 843,359 shares during the period. 98.63% of the stock is owned by institutional investors.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Read More

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.